Renewed PBS bid for Wegovy

PBAC to consider semaglutide listing for new indication of established CVD with obesity The PBAC will soon consider whether Novo Nordisk’s Wegovy (semaglutide 2.4mg) should be subsidised for Australians with established cardiovascular disease (eCVD) and overweight or obesity, without diabetes. Previous submissions by the sponsor for PBS listing of the drug for the indication of